Pacira BioSciences (PCRX) Stock Price, News & Analysis

Company Overview

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. The company has advanced clinical research in areas such as extended-release meloxicam formulations for soft tissue and orthopedic procedures, aiming to further expand its portfolio of non-opioid pain therapies. Pacira collaborates with healthcare providers and research partners to support clinical trials and to explore potential new indications for its proprietary technologies.

Founded in 2006 and headquartered in Parsippany, New Jersey, Pacira BioSciences markets its products throughout the United States and in select international territories. The company emphasizes education and training for healthcare professionals to ensure the safe and effective use of its therapies. Pacira’s operations encompass regulatory affairs, medical affairs, and commercial functions, all dedicated to advancing patient-centered approaches to pain management.

Key Stats

• Today's Range: $19.84 to $22.88
• 50-Day Range: $22.02 to $27.22
• 52-Week Range: $16.00 to $27.64
• Volume: 1.98 million shs
• Average Volume: 439,112 shs
• Market Capitalization: $989.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.40
• Consensus Rating: Hold

Pacira BioSciences Stock Analysis - MarketRank™

Pacira BioSciences scored higher than 87% of companies evaluated by MarketBeat, and ranked 144th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Pacira BioSciences has a consensus price target of $33.40, representing about 51.7% upside from its current price of $22.02.

Amount of Analyst Coverage

Pacira BioSciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.64%

Earnings Growth

Earnings for Pacira BioSciences are expected to grow by 6.64% in the coming year, from $2.41 to $2.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacira BioSciences is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacira BioSciences is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pacira BioSciences has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.37% of the float of Pacira BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 6.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacira BioSciences does not currently pay a dividend.

Dividend Growth

Pacira BioSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.89

Percentage of Shares Shorted

14.37% of the float of Pacira BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 6.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.07

News Sentiment

Pacira BioSciences has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Pacira BioSciences this week, compared to 8 articles on an average week.

Search Interest

3 people have searched for PCRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,267.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Pacira BioSciences is held by insiders.

Percentage Held by Institutions

99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PCRX Stock Analysis - Frequently Asked Questions

How have PCRX shares performed this year?

Pacira BioSciences' stock was trading at $18.84 at the beginning of 2025. Since then, PCRX shares have increased by 16.9% and is now trading at $22.02.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Tuesday, August, 5th. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Pacira BioSciences's quarterly revenue was up 1.7% on a year-over-year basis.
Read the conference call transcript.

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' top institutional investors include Rice Hall James & Associates LLC (0.53%), Assenagon Asset Management S.A. (0.52%), Pacer Advisors Inc. (0.45%) and Exchange Traded Concepts LLC (0.17%). Insiders that own company stock include David M Stack, Daryl Gaugler, Frank D Lee, Kristen Williams, Jonathan Slonin, Lauren Riker, Roy Winston, Charles A Reinhart III, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson and Marcelo Bigal.
View institutional ownership trends.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCRX
• CIK: 1396814
• Web: www.pacira.com
• Phone: (813) 553-6680
• Fax: 302-655-5049
• Employees: 720
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Pacira BioSciences: $33.40
• High Price Target: $65.00
• Low Price Target: $18.00
• Potential Upside/Downside: +51.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 9.14
• P/E Growth: N/A
• Net Income: -$99.56 million
• Net Margins: -18.08%
• Pretax Margin: -15.11%
• Return on Equity: 13.29%
• Return on Assets: 6.61%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 2.38
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $700.97 million
• Price / Sales: 1.41
• Cash Flow: $4.13 per share
• Price / Cash Flow: 5.33
• Book Value: $16.86 per share
• Price / Book: 1.31

Miscellaneous

• Outstanding Shares: 44,930,000
• Free Float: 42,057,000
• Market Cap: $989.36 million
• Optionable: Optionable
• Beta: 0.40